• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Actelion Ltd (ATLN) - Financial and Strategic SWOT Analysis Review

  • ID: 1292310
  • April 2015
  • 59 pages
  • GlobalData

FEATURED COMPANIES

  • Alpex Pharma SA
  • Cytos Biotechnology AG
  • F. Hoffmann-La Roche Ltd.
  • Merck Serono S.A.
  • Mymetics Corporation
  • Novartis AG
  • MORE

Actelion Ltd (ATLN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alpex Pharma SA
  • Cytos Biotechnology AG
  • F. Hoffmann-La Roche Ltd.
  • Merck Serono S.A.
  • Mymetics Corporation
  • Novartis AG
  • MORE

List of Tables
List of Figures
Section 1 - About the Company
Actelion Ltd - Key Facts
Actelion Ltd - Key Employees
Actelion Ltd - Key Employee Biographies
Actelion Ltd - Major Products and Services
Actelion Ltd - Pharmaceutical Pipeline Products Data
Actelion Ltd, Pipeline Products by Therapy Area
Actelion Ltd, Pipeline Products by Development Phase
Actelion Ltd - History
Actelion Ltd - Company Statement
Actelion Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Actelion Ltd - Business Description
Actelion Ltd - Corporate Strategy
Actelion Ltd - SWOT Analysis
SWOT Analysis - Overview
Actelion Ltd - Strengths
Strength - Focused R&D Activities
Strength - Portfolio of PAH Products
Strength - Cost Control
Actelion Ltd - Weaknesses
Weakness - Legal Proceedings
Weakness - Impending Loss of Exclusivity: Tracleer
Actelion Ltd - Opportunities
Opportunity - Products Pipeline
Opportunity - Market Potential: PAH
Opportunity - New Developments
Actelion Ltd - Threats
Threat - Influx of Generics
Threat - Uncertain R&D Outcomes
Threat - Stringent Government Regulations
Actelion Ltd - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Actelion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Actelion Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Actelion Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 16, 2015: Actelion delivers outstanding 2014 results
Oct 21, 2014: Actelion Delivers Strong Nine Months Results
Sep 04, 2014: Europe's Largest Biopharmaceutical Company Takes Big Leap into Procurement-Powered Business Performance with Zycus
Aug 05, 2014: PatientsLikeMe and Actelion to Develop New Patient-Reported Measure for Mycosis Fungoides type Cutaneous T-Cell Lymphoma
Jul 22, 2014: Actelion delivers strong half year operational and financial results
May 05, 2014: Management Change At Actelion - Roland Haefeli To Focus On Senior Advisory Role - Andrew Weiss New Head Of Investor Relations And Corporate Communications
Apr 17, 2014: Actelion Announces First Quarter 2014 Financial Results
Mar 13, 2014: Actelion Provides Update On Asahi Litigation
Feb 11, 2014: Actelion Again Delivers Strong Performance In 2013 - Opsumit Approved And Launched
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
Actelion Ltd, Key Facts
Actelion Ltd, Key Employees
Actelion Ltd, Key Employee Biographies
Actelion Ltd, Major Products and Services
Actelion Ltd, Number of Pipeline Products by Therapy Area
Actelion Ltd, Number of Pipeline Products by Development Stage
Actelion Ltd, Pipeline Products By Therapy Area and Development Phase
Actelion Ltd, History
Actelion Ltd, Subsidiaries
Actelion Ltd, Key Competitors
Actelion Ltd, Ratios based on current share price
Actelion Ltd, Annual Ratios
Actelion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Actelion Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Actelion Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Actelion Ltd, Pipeline Products by Therapy Area
Actelion Ltd, Pipeline Products by Development Phase
Actelion Ltd, Performance Chart (2010 - 2014)
Actelion Ltd, Ratio Charts
Actelion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Actelion Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015

Note: Product cover images may vary from those shown

Santhera Pharmaceuticals Holding AG
Novartis AG
Mymetics Corporation
Merck Serono S.A.
F. Hoffmann-La Roche Ltd.
Alpex Pharma SA
Cytos Biotechnology AG
Anavex Life Sciences Corp.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Grifols, S.A. Takeda Pharmaceutical Company Limited Alexion Pharmaceuticals Teva Pharmaceutical Industries Ltd. Endo International Plc. Essilor International S.A.